u/PeanutFew6895

You’ve probably noticed something deeply strange if you’ve looked at the valuation multiples across the quantum computing peer group. The companies generating the most revenue trade at the lowest multiples. The companies generating almost no revenue trade at the highest. It’s the complete inverse of how valuation is supposed to work — and it’s not a mistake or a market inefficiency. It’s actually internally consistent once you understand what these stocks are.

The chart says it all

Plot EV/NTM revenue against LTM revenue and you get a clean downward slope. D-Wave (QBTS) at $12.4M in trailing revenue trades at 448x forward revenue. Quantinuum (QNT), which IPO’d this week at $60 per share, sits at 421x on $17.1M trailing revenue. Rigetti (RGTI) at $10M trades at 285x. Then as you move right — more revenue, bigger business — the multiples compress sharply. Infleqtion (INFQ) at $33.6M in LTM revenue trades at just 68x. IonQ (IONQ), the sector’s revenue leader at $187M LTM, sits at 74x. The relationship is almost mechanical: the more revenue a company has, the less the market is willing to pay per dollar of it.

These aren’t revenue stocks. They’re options.

What you’re actually buying in any of these names is a call option on fault-tolerant quantum computing becoming commercially viable — an event the roadmaps place somewhere between 2028 and 2032 depending on who you believe. Quantinuum calls theirs Apollo, targeting 2029. IonQ has a parallel programme. The timeline is uncertain, the payoff if it arrives is potentially enormous, and current revenue has almost nothing to do with either variable.

In options pricing terms, a company that is generating meaningful cash flows from its quantum technology today has partially exercised its option early. It has revealed information about what quantum computing is worth right now — which turns out to be a modest amount, since today’s systems are still largely experimental tools for research labs and pharmaceutical companies running proof-of-concept workloads. The unexercised option — the company burning through cash with negligible revenue but a credible path to fault tolerance — retains maximum time value precisely because it hasn’t yet revealed what the technology is worth. The market rewards that uncertainty.

D-Wave is the clearest illustration

QBTS has been generating real, recurring QCaaS revenue longer than anyone else in this group. It has the most commercially proven product. It has paying enterprise and government customers. And it trades at 448x forward revenue — the highest multiple in the peer group. Why? Partly because its Q1’25 revenue spike of $15M was a one-off hardware sale to a German supercomputing centre that inflates the trailing number. But more fundamentally because the market is not valuing the annealing business at all — it’s pricing the company’s pivot toward gate-model quantum computing via its acquisition of Quantum Circuits, and the probability that the combination produces something relevant to the fault-tolerant future. The revenue is almost being ignored as noise from the wrong product line.

Rigetti is even more extreme: revenue has actually declined three years running, from $13M in FY2022 to $7M in FY2025. By any conventional framework this is a company in commercial distress. Yet the $7.2B market cap says otherwise. The market is betting entirely on whether the modular superconducting architecture scales to competitive qubit counts by 2027 — something that has nothing to do with the income statement today.

Quantinuum’s IPO crystallises the paradox

QNT priced above its $53–55 range at $60 per share, raised $1.68B, opened at $68, and then slid below its IPO price within two days as the broader quantum sector sold off hard — D-Wave, Rigetti, Infleqtion and QUBT all fell double digits on June 5, and the group has continued lower since. In its first days of trading QNT has swung between roughly $51 and $71. By any traditional metric a company with $30.9M in FY2025 revenue, 62% of it from a single Japanese research institution, carrying a $15.5B market cap is uninvestable. By the option-pricing framework, it’s a well-funded bet on the best gate fidelity in the industry and a 2029 fault-tolerant system.

The comparison with IonQ is instructive. Both use trapped-ion technology. IonQ has been public since 2021, has grown revenue to $187M LTM through a combination of organic growth and acquisitions, and trades at 74x forward revenue — among the lowest multiples in the group. It is being progressively re-rated from a pure technology option toward a genuine revenue business. That compression, from 300x+ two years ago to 74x today, is what the normalisation process looks like. Every company in this sector will eventually face the same transition. The question is which ones survive long enough to reach it.

What actually matters right now

Given that current revenue is largely irrelevant to these multiples, what should you actually be watching? Three things. First, bookings and remaining performance obligations — these are the leading indicators of future revenue recognition and the best signal of real commercial demand. Quantinuum had $79.3M in FY2025 bookings against $30.9M in revenue, which is encouraging. D-Wave reported $33.4M in Q1’26 bookings alone, the best quarter in its history. Second, cash burn relative to balance sheet — every company in this group raised heavily in 2024–2025 and has enough runway to reach the fault-tolerant era if they’re disciplined. Third, hardware milestones — gate fidelity, qubit count, error rates. These are the intermediate signals that tell you whether the option is moving in or out of the money.

Revenue will matter eventually. The chart will look different in three years. But right now, in this sector, more revenue is a signal that you’re monetising the present — and the market is paying for the future.

All data from SEC filings and stockanalysis.com. Prices as of June 8, 2026. Not investment advice.

Following several requests from the comments, I’ve updated the analysis to include Quantinuum, which prices on Nasdaq tomorrow under the ticker QNT at $53–$55 per share, targeting a $14.3 billion valuation. I’ve also corrected a few numbers from the original post — most notably QUBT’s FY2025 revenue was $0.68M, not $1.15M as I had it, and D-Wave’s full year was $24.6M not $25.4M. Sources are SEC 10-Q, 10-K and 8-K filings throughout.

The R&D chart is where Quantinuum’s story really begins
The most immediately striking thing about adding QNT to the comparison is what it does to the R&D chart. Even with IonQ excluded to keep the scale readable, Quantinuum sits in a completely different league — spending roughly $50 million per quarter on research and development, consistently and without interruption, while generating only $5–19 million in quarterly revenue depending on which quarter you look at. To put that in perspective: Rigetti, which has been public since 2022 and is valued at $8.6 billion, spends around $14 million per quarter on R&D. Infleqtion spends about $15 million. D-Wave is somewhere in the $10–30 million range depending on the quarter. Quantinuum is spending three to four times what its nearest peer spends, every single quarter, on science.

The reason is history. Quantinuum didn’t start as a startup — it was formed in 2021 through the merger of Honeywell Quantum Solutions and Cambridge Quantum Computing, and for the decade before that, Honeywell had been pouring capital into trapped-ion quantum research with no commercial pressure whatsoever. The S-1 discloses that the company has invested more than $2 billion in R&D over the past decade. That’s not a venture-backed growth company managing cash carefully — that’s an industrial giant funding a moonshot on its own balance sheet. The result is that by the time QNT comes to market, it has the most technically advanced commercial quantum system available. Helios achieves 99.92% two-qubit gate fidelity, which is genuinely the highest of any commercial system in operation. IonQ, which uses similar trapped-ion technology, has been chasing that number for years. Rigetti’s superconducting approach trades fidelity for speed. D-Wave’s annealing architecture is fundamentally different and not directly comparable on gate metrics.

So the R&D chart is less a cause for concern and more a statement of where Quantinuum sits in the technology hierarchy: it is the best-funded, most technically credible pure hardware company coming to public markets, built on a decade of work that its peers simply haven’t had access to.

The revenue picture is more complicated
Where it gets messy is when you look at what that $2 billion in R&D has commercially produced so far. FY2025 revenue was $30.9 million — a 35% increase over FY2024’s $23 million, which sounds reasonable until you dig into the composition. The Q1’25 revenue chart shows the starkest illustration of the problem: a single spike to $19.1 million, driven almost entirely by RIKEN, Japan’s national research institute, which accounted for 90% of that quarter’s revenue. The rest of 2025 ran at roughly $3.9–4 million per quarter. Then Q1’26 comes in at $5.2 million — down 73% year over year from that Q1’25 peak, because RIKEN dropped from 90% to just 7% of a much smaller number.

This pattern will be familiar to anyone who watched D-Wave’s Q1’25 spike, which I covered in the original post. D-Wave had a similar one-time event — its first hardware sale to Forschungszentrum Jülich in Germany — that created a $15 million quarter surrounded by $2–4 million quarters on either side. Both spikes happened to land in Q1’25, which makes them look like they’re telling the same story on the revenue chart. They’re not. D-Wave’s spike came from a new commercial product channel — an on-premises hardware sale to a research institution — while Quantinuum’s came from a large government research contract milestone. The structural implication is also different: D-Wave is now booking $33 million per quarter in new orders and has a $42 million remaining performance obligation backlog, suggesting revenue is genuinely building. Quantinuum’s $79.3 million in 2025 bookings is the equivalent signal, and it’s encouraging, but the recognition timing is entirely unclear.

How does QNT compare to the peer group on valuation?
At the IPO midpoint of $54, Quantinuum has a market cap of about $13.7 billion and — after accounting for the roughly $2.05 billion in post-IPO cash — an enterprise value of approximately $11.7 billion. On trailing twelve-month revenue of around $17.8 million, that implies an EV/LTM revenue multiple of 657x. On forward estimates of $32 million, EV/NTM comes to 366x.

Neither of those numbers is defensible in any traditional sense, but the relevant comparison is whether they’re defensible relative to peers. Rigetti trades at over 800x EV/LTM revenue and 348x EV/NTM. D-Wave trades at 791x LTM and 530x NTM. QUBT has a negative EV — meaning its cash pile exceeds its market cap — so the multiple is not meaningful. Infleqtion is the cheapest at 93x LTM and 83x NTM. IonQ, with the most credible revenue trajectory, is at 123x LTM and 91x NTM.

So on an EV/NTM basis, Quantinuum at 366x sits between the extremes — more expensive than IonQ and Infleqtion, cheaper than Rigetti and D-Wave on that metric. Given that Quantinuum has considerably better technology credentials than Rigetti and considerably more commercial momentum than D-Wave’s underlying QCaaS business, the relative positioning doesn’t look absurd. What it does look like is a company being priced on the Apollo thesis — the 2029 target to deliver the first fault-tolerant universal quantum computer — rather than anything happening in the income statement today.

The structural fine print matters
One thing the valuation tables don’t capture is the Up-C corporate structure Quantinuum is using for this IPO. Public investors in Class A shares get economic rights but limited governance influence. Honeywell retains approximately 49.1% of voting power and economic interest post-IPO via Class B shares, and the pre-IPO unitholders — Honeywell and Cambridge Quantum — are also party to a Tax Receivable Agreement that entitles them to 85% of any cash tax savings the company realises as units are exchanged. That’s a real long-term drain on cash that doesn’t show up in EBITDA. It’s the same structure used by a number of energy and tech companies over the years, and it works fine, but it means the public float — about 10.2% of total economic interest — is buying a minority stake in a Honeywell-controlled enterprise.

The other thing worth noting is that the IPO was originally filed at $45–50 per share for 21 million shares. By June 1st, it had been upsized to 26.5 million shares at $53–55, reportedly oversubscribed by more than 10x. Whether that demand reflects genuine conviction in the quantum thesis or is simply a function of sector momentum after a year in which D-Wave more than doubled and IonQ became the first quantum company to break $100 million in annual revenue is a question worth sitting with.

Bottom line
Quantinuum is the most technically serious company in this group. It has the best gate fidelity, the most R&D investment behind it, and a hardware roadmap that — if it executes — puts it at the centre of a fault-tolerant quantum future. What it doesn’t have is a revenue engine that justifies a $14 billion valuation today. FY2025 bookings of $79.3 million suggest the pipeline is building, but with a track record of extreme customer concentration and revenue that collapsed 73% year over year in the most recent quarter, the near-term execution risk is real.

The most useful comparison might not be to the other quantum stocks at all, but to what Honeywell is giving up. They spent more than a decade and $2 billion building this. They’re now selling 10% of it to the public at a $14 billion valuation. That tells you something about where they think the technology sits — and what they think the next decade might be worth.

Figures from SEC 10-Q/10-K/8-K filings and Quantinuum S-1/S-1A (May–June 2026). Not investment advice.

I spent some time digging into the financials of the five pure-play quantum hardware companies you can actually buy on a public exchange: IonQ (IONQ), Rigetti (RGTI), D-Wave (QBTS), Quantum Computing Inc. (QUBT), and the newest entrant Infleqtion (INFQ), which only listed in February 2026 via SPAC. Here’s what the numbers actually look like — and what they say about where each company stands.

The Revenue Picture
If you stack up quarterly revenues, one thing becomes immediately clear: IonQ has broken away from the pack in a way that no one else has come close to replicating. As recently as early 2024, all five companies were generating somewhere between $2M and $12M per quarter. By Q1 2026, IonQ is reporting $64.7M in a single quarter — a number that would have seemed science fiction two years ago. The growth is real, though a big chunk comes from acquisitions (ID Quantique, Oxford Ionics, Vector Atomic, Lightsynq), so it’s not purely organic. Full-year 2026 guidance has been raised to $260–270M.
Everyone else is on a very different trajectory. D-Wave had a spectacular Q1 2025 — $15M in a single quarter, up 509% year-over-year — but it turned out to be a one-time hardware sale to Forschungszentrum Jülich in Germany, the first research institution to buy an on-premises Advantage system. Strip that out and D-Wave’s run-rate is still $3–4M per quarter from cloud subscriptions. Rigetti is actually revenue-declining: from $13M in FY2022 down to roughly $7M TTM, even as the stock trades at a $8B+ market cap. QUBT had essentially no revenue to speak of until very recently, though Q1 2026 showed a jump to $3.7M following acquisitions of its own. Infleqtion is the quiet overachiever here — $32.5M in FY2025 revenue with a more predictable government-heavy contract base, though a big chunk comes from quantum sensing rather than computing.

The Cash Story
What’s arguably more interesting than revenue right now is what’s sitting on these balance sheets. Between 2024 and 2026, all five companies went on massive capital raises — and the result is a group of pre-profit businesses that are collectively sitting on billions of dollars in cash. IonQ holds $3.1B. QUBT has $1.4B despite generating almost no revenue. QBTS has $588M, RGTI $575M, and Infleqtion $569M post-SPAC. In several cases the cash position is so large relative to the business that the enterprise value (market cap minus net cash) is a small fraction of the headline valuation — or even negative in QUBT’s case. Investors are effectively paying for an option on the future, with the cash acting as a floor.

The Multiples
This is where things get uncomfortable. On trailing revenue, IonQ trades at roughly 105x EV/Revenue — stretched, but at least anchored to a real and rapidly growing revenue base. Rigetti trades at over 1,000x trailing revenue. QBTS looks reasonable on a trailing basis only because of the lumpy Q1 2025 hardware sale; on a normalised run-rate the multiple is similarly extreme. QUBT’s trailing revenue multiple is essentially unmeasurable given how small the revenue base is. Infleqtion, interestingly, is the cheapest of the group at roughly 70x EV/LTM revenue — and has the fastest path to EBITDA breakeven given its narrowing losses and sensing revenue base.

What to Make of All This
The honest conclusion is that these are not traditional equities you value on earnings or cash flows — they’re deep technology bets on which architecture wins and who captures government and enterprise contracts over the next decade. The market is pricing in a world where quantum computing becomes commercially meaningful at scale, and assigning most of the option value to the companies that have already demonstrated they can raise capital, sign customers, and ship hardware. IonQ has the most credible commercial story right now. Infleqtion is the most underappreciated on valuation. Rigetti is the hardest to justify on fundamentals. And QUBT is, essentially, a $2.7B bet on photonic manufacturing — with $1.4B of that sitting in a bank account.

One thing they all share: R&D spending that dwarfs revenue, operating losses that will persist for years, and share counts that keep growing as they tap equity markets. If you’re investing in any of these, you’re not buying a business — you’re buying a thesis.

All figures sourced from SEC filings (10-K, 10-Q, 8-K) and company press releases. Prices as of May 28, 2026. Not investment advice.